Continue to site >
Trending ETFs

Name

Price

Aum/Mkt Cap

YIELD & DIV

Exp Ratio

Watchlist

$106.08

$19.1 B

0.00%

$0.00

0.76%

Vitals

YTD Return

7.3%

1 yr return

15.1%

3 Yr Avg Return

18.1%

5 Yr Avg Return

18.6%

Net Assets

$19.1 B

Holdings in Top 10

36.6%

52 WEEK LOW AND HIGH

$107.8
$94.82
$117.14

Expenses

OPERATING FEES

Expense Ratio 0.76%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 41.70%

Redemption Fee N/A


Min Investment

Standard (Taxable)

$2,500

IRA

$1,000


Fund Classification

Fund Type

Open End Mutual Fund

Investment Style

Health


Name

Price

Aum/Mkt Cap

YIELD & DIV

Exp Ratio

Watchlist

$106.08

$19.1 B

0.00%

$0.00

0.76%

PRHSX - Profile

Distributions

  • YTD Total Return 7.3%
  • 3 Yr Annualized Total Return 18.1%
  • 5 Yr Annualized Total Return 18.6%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.05%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    T. Rowe Price Health Sciences Fund
  • Fund Family Name
    T. Rowe Price
  • Inception Date
    Dec 29, 1995
  • Shares Outstanding
    N/A
  • Share Class
    No Load
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Ziad Bakri

Fund Description

The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-capitalization companies. It is non-diversified.


PRHSX - Performance

Return Ranking - Trailing

Period PRHSX Return Category Return Low Category Return High Rank in Category (%)
YTD 7.3% -81.1% 25.3% 32.71%
1 Yr 15.1% -28.4% 33.9% 29.65%
3 Yr 18.1%* 2.4% 31.2% 7.43%
5 Yr 18.6%* 3.8% 31.1% 10.49%
10 Yr 20.5%* 8.4% 21.8% 4.03%

* Annualized

Return Ranking - Calendar

Period PRHSX Return Category Return Low Category Return High Rank in Category (%)
2020 21.4% -13.6% 178.2% 25.43%
2019 21.5% 3.8% 63.8% 42.76%
2018 -4.7% -49.7% 21.5% 38.69%
2017 19.1% -59.8% 54.4% 50.37%
2016 -14.2% -36.6% 11.6% 50.00%

Total Return Ranking - Trailing

Period PRHSX Return Category Return Low Category Return High Rank in Category (%)
YTD 7.3% -81.1% 25.3% 32.71%
1 Yr 15.1% -30.4% 31.1% 31.98%
3 Yr 18.1%* -15.9% 31.2% 6.70%
5 Yr 18.6%* -7.4% 31.1% 8.05%
10 Yr 20.5%* 8.4% 21.8% 3.73%

* Annualized

Total Return Ranking - Calendar

Period PRHSX Return Category Return Low Category Return High Rank in Category (%)
2020 21.4% -13.6% 178.2% 25.43%
2019 21.5% 3.8% 63.8% 42.76%
2018 -4.7% -25.3% 22.2% 45.99%
2017 19.1% -10.8% 54.4% 61.48%
2016 -14.2% -36.6% 11.6% 59.38%

NAV & Total Return History


PRHSX - Holdings

Concentration Analysis

PRHSX Category Low Category High PRHSX % Rank
Net Assets 19.1 B 490 K 51.6 B 3.33%
Number of Holdings 205 3 474 4.58%
Net Assets in Top 10 7.06 B 2.18 K 21.1 B 2.50%
Weighting of Top 10 36.59% 11.8% 100.0% 70.00%

Top 10 Holdings

  1. Aggregate Miscellaneous Equity 8.64%
  2. Aggregate Miscellaneous Equity 8.64%
  3. Aggregate Miscellaneous Equity 8.64%
  4. Aggregate Miscellaneous Equity 8.64%
  5. Aggregate Miscellaneous Equity 8.64%
  6. Aggregate Miscellaneous Equity 8.64%
  7. Aggregate Miscellaneous Equity 8.64%
  8. Aggregate Miscellaneous Equity 8.64%
  9. Aggregate Miscellaneous Equity 8.64%
  10. Aggregate Miscellaneous Equity 8.64%

Asset Allocation

Weighting Return Low Return High PRHSX % Rank
Stocks
92.12% 0.09% 101.13% 95.83%
Other
7.97% -23.02% 7.97% 0.42%
Preferred Stocks
0.00% 0.00% 7.04% 60.00%
Convertible Bonds
0.00% 0.00% 0.21% 57.08%
Bonds
0.00% 0.00% 14.85% 58.75%
Cash
-0.09% -0.40% 99.91% 97.08%

Stock Sector Breakdown

Weighting Return Low Return High PRHSX % Rank
Healthcare
98.80% 61.59% 100.00% 65.00%
Basic Materials
1.03% 0.00% 8.42% 12.08%
Financial Services
0.17% 0.00% 1.85% 23.75%
Utilities
0.00% 0.00% 1.47% 55.83%
Technology
0.00% 0.00% 19.99% 62.92%
Real Estate
0.00% 0.00% 5.81% 57.92%
Industrials
0.00% 0.00% 9.31% 61.25%
Energy
0.00% 0.00% 0.76% 55.83%
Communication Services
0.00% 0.00% 7.14% 57.92%
Consumer Defense
0.00% 0.00% 28.15% 61.25%
Consumer Cyclical
0.00% 0.00% 17.48% 59.58%

Stock Geographic Breakdown

Weighting Return Low Return High PRHSX % Rank
US
82.16% 0.09% 100.00% 63.75%
Non US
9.96% 0.00% 42.77% 55.83%

PRHSX - Expenses

Operational Fees

PRHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.76% 0.08% 2.91% 46.81%
Management Fee 0.64% 0.00% 1.25% 51.67%
12b-1 Fee N/A 0.00% 1.00% 4.17%
Administrative Fee 0.15% 0.03% 0.25% 75.51%

Sales Fees

PRHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 0.00% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

PRHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PRHSX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 41.70% 0.00% 256.00% 40.61%

PRHSX - Distributions

Dividend Yield Analysis

PRHSX Category Low Category High PRHSX % Rank
Dividend Yield 0.00% 0.00% 2.44% 58.58%

Dividend Distribution Analysis

PRHSX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Semi-Annually Semi-Annually

Net Income Ratio Analysis

PRHSX Category Low Category High PRHSX % Rank
Net Income Ratio -0.05% -2.54% 1.92% 50.29%

Capital Gain Distribution Analysis

PRHSX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually

Dividend Payout History

View More +

PRHSX - Fund Manager Analysis

Managers

Ziad Bakri


Start Date

Tenure

Tenure Rank

Apr 01, 2016

5.67

5.7%

Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban

Tenure Analysis

Category Low Category High Category Average Category Mode
0.06 24.22 6.7 1.62